Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.56 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.34 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504081 | 0.89 | ELANE (0.67) | ELANECTRB1 | |
| SCHEMBL6402809 | 0.82 | CTRB1 (0.51) | ELANECTRB1KCNQ4KCNQ5LCK | |
| SCHEMBL6866267 | 0.82 | ELANE (0.80) | ELANECTRB1LCK | |
| SCHEMBL6637344 | 0.78 | ELANE (0.51) | ELANECTRB1 | |
| SCHEMBL6638795 | 0.77 | ELANE (0.61) | ELANECTRB1LCKCTSSCTSK | |
| SCHEMBL6508215 | 0.77 | ELANE (0.51) | ELANECTRB1 | |
| SCHEMBL6636149 | 0.77 | CTRB1 (0.53) | ELANECTRB1LCKCCNCCDK8 | |
| SCHEMBL6713458 | 0.76 | ELANE (0.53) | ELANECTRB1 | |
| SCHEMBL6637600 | 0.76 | ELANE (0.57) | ELANECTRB1CTSK | |
| SCHEMBL6636428 | 0.76 | ELANE (0.57) | ELANECTRB1KCNQ4KCNQ5LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6806269-B1 | EFFECTIVE AT LOWER CONCENTRATIONS; SUCH AS 6-(((1,1-DIMETHYL-ETHOXY)CARBONYL)AMINO)-5-METHYL-2-(METHYL(PHENYLMETHYL) -AMINO)-4H-3,1-BENZOXAZIN-4-ONE | G. D. SEARLE & COP | 2004-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | ELANE 1052/4885CTRB1 3288/4885KCNQ4 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.